Switch theme
Sign up to access all valuation multiples
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
2020
105
LTM Revenue n/a
LTM EBITDA -$227M
$15.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Summit Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$227M.
In the most recent fiscal year, Summit Therapeutics achieved revenue of n/a and an EBITDA of -$596M.
Summit Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Summit Therapeutics valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.7M | n/a | n/a | n/a | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$71.9M | -$596M | -$220M | -$227M | XXX |
| EBITDA Margin | -10194% | -Infinity% | -Infinity% | -Infinity% | XXX |
| Net Profit | -$88.6M | -$78.8M | -$615M | XXX | XXX |
| Net Margin | -12568% | -Infinity% | -Infinity% | XXX | XXX |
| Net Debt | n/a | $166M | $28.6M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Summit Therapeutics's stock price is $22.
Summit Therapeutics has current market cap of $16.3B, and EV of $15.9B.
See Summit Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.9B | $16.3B | XXX | XXX | XXX | XXX | $-0.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Summit Therapeutics has market cap of $16.3B and EV of $15.9B.
Summit Therapeutics's trades at n/a LTM EV/Revenue multiple, and -69.7x LTM EBITDA.
Analysts estimate Summit Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Summit Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $15.9B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -72.2x | XXX | XXX | XXX |
| P/E | -74.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSummit Therapeutics's NTM/LTM revenue growth is Infinity%
Summit Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Summit Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Summit Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Summit Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -63% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Summit Therapeutics acquired XXX companies to date.
Last acquisition by Summit Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Summit Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Summit Therapeutics founded? | Summit Therapeutics was founded in 2020. |
| Where is Summit Therapeutics headquartered? | Summit Therapeutics is headquartered in United States of America. |
| How many employees does Summit Therapeutics have? | As of today, Summit Therapeutics has 105 employees. |
| Who is the CEO of Summit Therapeutics? | Summit Therapeutics's CEO is Dr. Mahkam Zanganeh. |
| Is Summit Therapeutics publicy listed? | Yes, Summit Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Summit Therapeutics? | Summit Therapeutics trades under SMMT ticker. |
| When did Summit Therapeutics go public? | Summit Therapeutics went public in 2015. |
| Who are competitors of Summit Therapeutics? | Similar companies to Summit Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Summit Therapeutics? | Summit Therapeutics's current market cap is $16.3B |
| What is the current EBITDA of Summit Therapeutics? | Summit Therapeutics's last 12-month EBITDA is -$227M. |
| What is the current EV/EBITDA multiple of Summit Therapeutics? | Current EBITDA multiple of Summit Therapeutics is -69.7x. |
| Is Summit Therapeutics profitable? | Yes, Summit Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
